Towards Healthcare
U.S. Drug Screening Market to Soar USD 2.79 Billion by 2025

U.S. Drug Screening Market Expands in 2025 as Intelligent Bio Solutions Eyes U.S. Approval for Fingerprint Testing

Based on market forecasts, the global U.S. drug screening market, projected at USD 2.70 billion in 2024, is expected to reach USD 3.84 billion by 2034, growing at a CAGR of 3.64% over the forecast period. The U.S. drug screening market is growing rapidly due to growing drug addiction and rising production of synthetic drugs. 

Content

  • Insight Code: 5839
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The U.S. drug screening market is projected to reach USD 3.84 billion by 2034, growing at a CAGR of 3.64% from 2024 to 2034.

The U.S. drug screening market includes five segments such as by product & services, by sample type, by drug class detected, by end-user, and by technology.

Some key players include Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings (LabCorp), Abbott Laboratories (Abbott Toxicology), Alere Inc. (now part of Abbott), Thermo Fisher Scientific Inc., Orasure Technologies, Inc., etc.

Key trends include rising collaboration among key market players and growing demand from neighboring and lower-income countries.

Drug testing provides important information about the compounds included in drug samples. By using this information to completely understand what is in their substance or substances, PWUD may be able to make better usage decisions and reduce their chance of overdose.

The accuracy of urine and saliva tests depends on the time period in issue, since they are more effective at identifying recent usage.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.
Any Questions